Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases-Reference-Cited by-同舟云学术

Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases

Published:2023-10-24 Issue:11 Volume:25 Page:1475-1488
ISSN:1523-3782
Container-title:Current Cardiology Reports
language:en
Short-container-title:Curr Cardiol Rep

Author:

Behrooz Leili,Lenneman Carrie G.,Hamburg Naomi M.^ORCID

Abstract

Abstract Purpose of Review In this review, the impact of obesity on cardiovascular disease in women and emerging anti-obesity pharmacologic treatments are discussed. Recent Findings Robust evidence demonstrates the burden of obesity across the lifespan in women and links obesity to a diverse set of cardiovascular diseases. Female-specific risk factors including sex hormones and pregnancy factors intersect with obesity and cardiovascular risk. Sustained weight loss has potential for cardiovascular benefits. Recent trials demonstrate cardiovascular benefits of emerging agents with weight loss effects including GLP-1 RA and SGLT2 inhibitors in women. Summary Treatment and prevention strategies for cardiovascular disease in obese women should include integration of weight management strategies including the targeted use of emerging pharmacologic therapies.

Funder

American Heart Association

National Heart, Lung, and Blood Institute

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11886-023-01961-z.pdf

Reference172 articles.

1. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397:2385–438. https://doi.org/10.1016/S0140-6736(21)00684-X.

2. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. https://doi.org/10.1016/j.metabol.2022.155217.

3. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147:e93–621. https://doi.org/10.1161/CIR.0000000000001123.

4. Centers for Disease Control Obesity Data. 2023. https://www.cdc.gov/obesity/data/adult.html. Accessed 14 Aug.

5. Lin X, Xu Y, Xu J, Pan X, Song X, Shan L, et al. Global burden of noncommunicable disease attributable to high body mass index in 195 countries and territories, 1990–2017. Endocrine. 2020;69:310–20. https://doi.org/10.1007/s12020-020-02352-y.